Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2013, Vol. 18 ›› Issue (7): 764-768.

Previous Articles     Next Articles

Relationship between ERCC1,Bcl-2 expression and cisplatin intervention in human lung adenocarcinoma cell lines

JIN Yi-feng1, HE Bei2, LIU Dong-hua1, WAN Ying1   

  1. 1Department of Respiratory,the Affiliated Yijishan Hospital of Wannan Medical College,Wuhu 241001,Anhui,China;
    2Department of Respiratory, Anqing City Hospital , Anqing 241001,Anhui,China
  • Received:2013-03-21 Revised:2013-06-07 Online:2013-07-26 Published:2013-06-20

Abstract: AIM: To study the relationship between the expressions of ERCC1, Bcl-2 and the effect of cisplatin in human lung adenocarcinoma cell lines,which suggested that the effects of ERCC1, Bcl-2 in cisplatin resistance effect.METHODS: A549 and A549/DDP cell lines were collected in the study,then the resistance of A549/DDP cells was measured by MTT assay.The expressions of ERCC1, Bcl-2 mRNA and protein after different concentrations' and different time' intervention were measured by immunocytohistology SABC assay and RT-PCR respectively.RESULTS: After treating with 10 μg/mL cisplatin for 12 h, the expressions of ERCC1, Bcl-2 mRNA and protein were increased in A549 cells; With the extension of time, the expressions of ERCC1 and Bcl-2 mRNA were increased gradually, they reached the peak levels in 72 h group.After treating with 5 μg/mL cisplatin for 24 h, the expressions of ERCC1, Bcl-2 mRNA and protein was increased in A549 cells.With the increase of concentration, the expressions of ERCC1 and Bcl-2 mRNA were increased gradually ,they reached the highest levels in 20 μg/mL group.Compared with the paremtal cells, the expressions of ERCC1 and Bcl-2 mRNA and protein were increased significantly in A549/DDP cells.CONCLUSION: With increasing concentrations of cisplatin and action time, the expressions of ERCC1, Bcl-2 mRNA and protein are increased in A549 cells,then speculates that ERCC1 and Bcl-2 may be involved in cisplatin acquired resistance.

Key words: Lung cancer, Cisplatin, Resistance, ERCC1, Bcl-2

CLC Number: